Marika Lappalainen

Marika Lappalainen

Auto-generated profile, based on publicly available information

Marika Lappalainen

Department of Medicine, Kuopio University Hospital, Wellbeing Services County of North Savo

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2018 in Disease Markers
Verified
Journal Article
Open access
PDF file
MLMarika Lappalainen
Marika Lappalainen
JJJenna Jokkala
Jenna Jokkala
AJAuni Juutilainen
Auni Juutilainen
SHSari Hämäläinen
Sari Hämäläinen
IKIrma Koivula
Irma Koivula
KPKari Pulkki
Kari Pulkki
Background. Novel potential small molecular biomarkers for sepsis were analyzed with nontargeted metabolite profiling to find biomarkers for febrile neutropenia after intensive chemotherapy for hematological malignancies.Methods. Altogether, 85 patients were included into this prospective study at the start of febrile neutropenia after intensive chemotherapy for acute myeloid leukemia or after autologous stem cell transplantation. The plasma samples for the nontargeted metabolite profiling analysis by liquid chromatography-mass spectrometry were taken when fever rose over 38° and on the next morning.Results. Altogether, 90 differential molecular features were shown to explain the differences between patients with complicated (bacteremia, severe sepsis, or fatal outcome) and noncomplicated courses of febrile neutropenia. The most differential compounds were an androgen hormone, citrulline, and phosphatidylethanolamine PE(18:0/20:4). The clinical relevance of the findings was evaluated by comparing them with conventional biomarkers like C-reactive protein and procalcitonin.Conclusion. These results hold promise to find out novel biomarkers for febrile neutropenia, including citrulline. Furthermore, androgen metabolism merits further studies.

2 August 2020 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
MLMarika Lappalainen
Marika Lappalainen
SHSari Hämäläinen
Sari Hämäläinen
TRTuomo Romppanen
Tuomo Romppanen
KPKari Pulkki
Kari Pulkki
MPMarja Pyörälä
Marja Pyörälä
AJAuni Juutilainen
Auni Juutilainen

13 July 2021 in Clinical and Experimental Medicine
Verified
Journal Article
Open access
PDF file
CICarina Intke
Carina Intke
SKSini Korpelainen
Sini Korpelainen
MLMarika Lappalainen
Marika Lappalainen
MVMatti Vänskä
Matti Vänskä
SHSari Hämäläinen
Sari Hämäläinen
APAnna-Kaisa Purhonen
Anna-Kaisa Purhonen
The study aim was to determine the benefit of the measurement of serum caspase-cleaved cytokeratin-18 (CK-18) fragment as a prognostic marker of febrile neutropenia (FN) in hematological patients. The study population consisted of 86 consecutive patients with FN who received intensive chemotherapy for hematological malignancy at the adult hematology ward of Kuopio University Hospital. Twenty-three patients (27%) had acute myeloid leukemia, and 63 patients (73%) were autologous stem cell transplant recipients. Serum caspase-cleaved CK-18 fragment M30, C-reactive protein (CRP) and procalcitonin (PCT) were measured at the onset of FN (d0), on day 1 (d1), and on day 2 (d2). Eight patients (9%) developed severe sepsis, including three patients with septic shock. Eighteen patients (21%) had a blood culture-positive infection. Serum CK-18 fragment peaked on the first day after fever onset in patients with severe sepsis. Higher CK-18 level was associated with severe sepsis, intensive care unit treatment, and fatal outcome, but not with blood culture positivity. In ROC curve analysis, d1 serum CK-18 fragment predicted severe sepsis with an area under the curve (AUC) of 0.767, CRP with an AUC of 0.764, and PCT with an AUC of 0.731. On d2, the best predictive capacity was observed for CRP with an AUC of 0.832. The optimal cutoff of caspase-cleaved CK-18 fragment M30 for predicting severe sepsis was 205 U/L on d1. In hematological patients, serum CK-18 fragment was found to be a potential prognostic marker of severe sepsis at early stages of FN.

17 February 2017 in Scandinavian Journal of Clinical and Laboratory Investigation
Verified
Journal Article
Closed access
MLMarika Lappalainen
Marika Lappalainen
SHSari Hämäläinen
Sari Hämäläinen
AJAuni Juutilainen
Auni Juutilainen
IKIrma Koivula
Irma Koivula
KPKari Pulkki
Kari Pulkki
EJEsa Jantunen
Esa Jantunen
Asymmetric dimethylarginine (ADMA) has been recognized as an independent prognostic factor for sepsis mortality in intensive care units. No data are available on kinetics or prognostic value of ADMA in hematological patients. We evaluated the ability of ADMA to act as a predictor for complicated course of febrile neutropenia, defined as bacteremia and/or septic shock in adult hematological patients receiving intensive chemotherapy. This prospective study included 87 adult hematological patients with febrile neutropenia after an intensive chemotherapy for acute myeloid leukemia (AML) or after an autologous stem cell transplantation (ASCT). Plasma ADMA and serum C-reactive protein (CRP) levels were measured from the onset of fever (d0) and for 2 days (d1–d2) thereafter. The levels of ADMA were stable or had only minimal changes during the study period. There was no difference between the levels at any time-point in patients having complicated course compared to those without it. On the other hand, CRP levels were significantly higher on d1 (p = 0.016) in patients with bacteremia and/or septic shock than in those without. ADMA was not able to differentiate hematological patients with a complicated course from those without complications. Elevated ADMA levels are probably associated with organ dysfunction, which is rare in this group of patients, of whom about 95% can be successfully managed at the hematology ward.

16 December 2025 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
SBStefan Becker
Stefan Becker
MAMiika Arvonen
Miika Arvonen
MLMarika Lappalainen
Marika Lappalainen
EJEsa Jantunen
Esa Jantunen
KPKari Pulkki
Kari Pulkki
SHSari Hämäläinen
Sari Hämäläinen
Febrile neutropenia (FN) is a common complication of chemotherapy and potentially fatal. It is often associated with mucositis. Timely recognition of complications enables early supportive treatment and potentially reduces mortality. Common diagnostic parameters are often nonspecific or have slow kinetics. This study examines the applicability of mucosa-related biomarkers in the recognition of complicated course among 78 adult hematologic patients with FN after intensive chemotherapy. Plasma concentrations of citrulline, intestinal fatty acid binding protein (I-FABP), zonula occludens-1 (ZO-1) and alpha-1 acid glycoprotein (α1AGP), as well as C-reactive protein (CRP) and procalcitonin (PCT), were measured at the onset of fever and the following two days. All except ZO-1 showed a significant trend. Concentrations of CRP, PCT, citrulline and α1AGP were higher with a complicated course. Patients with severe sepsis had higher levels of PCT and lower levels of I-FABP. In conclusion, measurement of mucosa-related biomarkers might help predict the course of FN.